XML 53 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment and Geographic Information
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Segment and Geographic Information

14.

Segment and Geographic Information

The Company has determined that the chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews financial information presented for the Company’s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.

Geographic Revenues

Geographic revenues, which are based on the bill-to region, are as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Europe

 

$

112,916

 

 

$

110,861

 

 

$

151,736

 

Japan (related party)

 

 

100,002

 

 

 

20,111

 

 

 

31,323

 

All other

 

 

40

 

 

 

24

 

 

 

130

 

Total revenue

 

$

212,958

 

 

$

130,996

 

 

$

183,189

 

Geographic Long-Lived Assets

Property and equipment, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2018

 

 

2017

 

United States

 

$

103,539

 

 

$

107,228

 

China

 

 

23,659

 

 

 

22,248

 

Total property and equipment

 

$

127,198

 

 

$

129,476

 

Customer Concentration

Substantially all of the Company’s revenues to date have been generated from the following collaboration partners that respectively accounted for more than 10% of the Company’s total revenue and accounts receivable:

 

 

Percentage of Revenue

 

 

Percentage of Accounts Receivable

 

 

 

Years Ended December 31,

 

 

December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

 

2018

 

 

2017

 

Astellas—Related party

 

 

47

%

 

 

15

%

 

 

17

%

 

 

74

%

 

 

47

%

AstraZeneca

 

 

53

%

 

 

85

%

 

 

83

%

 

 

26

%

 

 

53

%